Davy James, Managing Editor

Study estimates United States is wasting $45 million every month that biosimilar Zarxio is not on the market.

Top stories of the week on Specialty Pharmacy Times.

Highly effective cholesterol-lowering drug to challenge Regeneron & Sanofi's Praluent.

Blocking oxygen sensor may improve colorectal cancer treatment.

Cabozantinib is a potential treatment for patients with advanced renal cell carcinoma who received one prior therapy.

Promacta use now includes young children with chronic immune thrombocytopenia.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Processing speed found to hinder MS patients in everyday life.

Ongoing clinical trial testing guadecitabine in Myelodysplastic syndromes and acute myelogenous leukemia.

Children vaccinated before starting HIV therapy found to be at risk.

Top stories of the week on Specialty Pharmacy Times from August 17 to 21.

More companies are requiring prior authorization before specialty drugs are purchased under employer health plan.

Women and individuals who suffered childhood sexual abuse among most vulnerable IBD patients.

Debate continues around eligibility requirements for pricey new high cholesterol drug class.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses URAC specialty practice standards.

Many people who test negative for BRCA1 and BRCA2 harbor other harmful genetic mutations.

Regular exercise may decrease MS symptoms.

Combining chemotherapy with immune blocker could prevent cancer from growing back.

A look back at the top stories of the week on Specialty Pharmacy Times.

Intra-abdominal fat cells associated with the progression of Crohn's disease and ulcerative colitis.

Ethicists worried trials will threaten scientific rigor and efficacy.

David Lassen, chief clinical officer at Prime Therapeutics, discusses changes in store for the field of specialty pharmacy in the coming years.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

Salt found to influence immune cells that cause the disease.

Weight cycling may influence the biological processes that can lead to cancer.

High cost of research and development causes less investment by pharmaceutical firms.

A look back at the top stories of the week on Specialty Pharmacy Times.

Researchers explore the use of probiotics to alter communication between brain and immune system.

Updated information includes drug-drug interaction.